Chronic kidney disease and heart failure-Bidirectional close link and common therapeutic goal

Journal of Cardiology

Volumn 57, Issue 1, 2011, Pages 8-17

  Shiba, Nobuyuki ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE inhibitor; Heart failure; Kidney

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANEMIA; CHRONIC KIDNEY DISEASE; DISEASE CLASSIFICATION; HEART FAILURE; HIGH RISK POPULATION; HUMAN; JAPAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW;

AGED; FEMALE; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; SYNDROME;

EID: 78650534056     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.09.004     Document Type: Review

References (74)

1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39(SUPPL. 1):S1-266.
2. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., Van Lente F., Levey A.S. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
3. Imai E., Horio M., Watanabe T., Iseki K., Yamagata K., Hara S., Ura N., Kiyohara Y., Moriyama T., Ando Y., Fujimoto S., Konta T., Yokoyama H., Makino H., Hishida A., et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009, 13:621-630.
4. Stevens P.E., O'Donoghue D.J., de Lusignan S., Van Vlymen J., Klebe B., Middleton R., Hague N., New J., Farmer C.K. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007, 72:92-99.
5. Chadban S.J., Briganti E.M., Kerr P.G., Dunstan D.W., Welborn T.A., Zimmet P.Z., Atkins R.C. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am soc Nephrol 2003, 14(SUPPL. 2):S131-S138.
6. Chronic kidney disease identified in the claims data. 2009 Annual Data Report, United States Renal Data System. Available at http://www.usrds.org/.
7. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
8. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L., Kelepouris E., Klag M.J., Parfrey P., Pfeffer M., Raij L., Spinosa D.J., Wilson P.W. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003, 42:1050-1065.
9. American Heart Association Heart Disease and Stroke Statistics - 2005 Update 2005, American Heart Association, Dallas, TX.
10. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442.
11. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-90.
12. Stewart S., Jenkins A., Buchan S., McGuire A., Capewell S., McMurray J.J. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002, 4:361-371.
13. Poole-Wilson P.A. History, definition and classification of heart failure. Heart failure 1 1997, Churchill Livingstone, New York, p. 269-77.
14. Shulman N.B., Ford C.E., Hall W.D., Blaufox M.D., Simon D., Langford H.G., Schneider K.A. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection And Follow-Up Program Cooperative Group. Hypertension 1989, 13(SUPPL.):I80-93.
15. Cheung A.K., Sarnak M.J., Yan G., Berkoben M., Heyka R., Kaufman A., Lewis J., Rocco M., Toto R., Windus D., Ornt D., Levey A.S. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004, 65:2380-2389.
16. Kottgen A., Russell S.D., Loehr L.R., Crainiceanu C.M., Rosamond W.D., Chang P.P., Chambless L.E., Coresh J. Reduced kidney function as a risk factor for incident heart failure: the Atheroscleroosis Risk in Communities (ARIC) study. J Am Soc Nephrol 2007, 18:1307-1315.
17. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:681-689.
18. Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., Hampton J.R., van Veldhuisen D.J. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
19. Mahon N.G., Blackstone E.H., Francis G.S., Starling R.C., Young J.B., Lauer M.S. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002, 40:1106-1113.
20. McClellan W.M., Flanders W.D., Langston R.D., Jurkovitz C., Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospital: a population-based study. J Am Soc Nephrol 2002, 13:1928-1936.
21. Kearney M.T., Fox K.A., Lee A.J., Prescott R.J., Shah A.M., Batin P.D., Baig W., Lindsay S., Callahan T.S., Shell W.E., Eckberg D.L., Zaman A.G., Williams S., Neilson J.M., Nolan J. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 2002, 40:1801-1808.
22. Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., Granger C.B., Michelson E.L., Ostergren J., Cornel J.H., de Zeeuw D., Pocock S., van Veldhuisen D.J. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
23. Go A.S., Yang J., Ackerson L.M., Lepper K., Robbins S., Massie B.M., Shlipak M.G. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure. The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113:2713-2723.
24. Shiba N., Matsuki M., Takahashi J., Tada T., Watanabe J., Shimokawa H. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J 2008, 72:173-178.
25. Hamaguchi S., Tsuchihashi-Makaya M., Kinugawa S., Yokota T., Ide T., Takeshita A., Tsutsui H. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009, 73:1442-1447. The JCARE-CARD Investigators.
26. Ahmed A., Rich M.W., Sanders P.W., Perry G.J., Bakris G.L., Zile M.R., Love T.E., Aban I.B., Shlipak M.G. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007, 99:393-398.
27. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Gong Y., Liu P.P. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
28. Nohria A., Hasselblad V., Stebbins A., Pauly D.F., Fonarow G.C., Shah M., Yancy C.W., Califf R.M., Stevenson L.W., Hill J.A. Cardiorenal interactions-insights from the ESCAPE trial. J Am Coll Cardiol 2008, 51:1268-1274.
29. Liang K.V., Williams A.W., Greene E.L., Redfield M.M. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008, 36:S75-88.
30. Adams K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Costanzo M.R., Abraham W.T., Berkowitz R.L., Galvao M., Horton D.P. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J 2005, 149:209-216. ADHERE Scientific Advisory Committee and Investigators.
31. Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 2007, 50:768-777.
32. Takagi A., Iwama Y., Yamada A., Aihara K., Daida H. Estimated glomerular filtration rate is an independent predictor for mortality of patients with acute heart failure. J Cardiol 2010, 55:317-321.
33. Tang W.H.W., Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart 2010, 96:255-260.
34. Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
35. McClellan W., Aronoff S.L., Bolton W.K., Hood S., Lorber D.L., Tang K.L., Tse T.F., Wasserman B., Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004, 20:1501-1510.
36. Anker S.D., Negassa A., Coats A.J., Afzal R., Poole-Wilson P.A., Cohn J.N., Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003, 361:1077-1083.
37. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002, 16:87-96.
38. Maggioni A.P., Anand I., Gottlieb S.O., Latini R., Tognoni G., Cohn J.N. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002, 40:1414-1421. Val-HeFT Investigators (Valsartan Heart Failure Trial).
39. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., Brosh D., Laniado S., Schwartz D., Yachnin T., Shapira I., Gavish D., Baruch R., Koifman B., Kaplan C., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737-1744.
40. Kazory A., Ross E.A. Anemia: the point of convergence or divergence for kidney disease and heart failure. J Am Coll Cardiol 2009, 53:639-647.
41. Herrlin B., Nyquist O., Sylven C. Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study. Br Heart J 1991, 66:199-205.
42. Pappas K.D., Gouva C.D., Katopodis K.P., Nikolopoulos P.M., Korantzopoulos P.G., Michalis L.K., Goudevenos J.A., Siamopoulos K.C. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 and 4): effects on cardiac performance. Cardiovasc Drugs Ther 2008, 22:37-44.
43. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098. CHOIR Investigators.
44. Drüeke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084. CREATE Investigators.
45. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., Feyzi J.M., Ivanovich P., Kewalramani R., Levey A.S., Lewis E.F., McGill J.B., McMurray J.J., Parfrey P., Parving H.H., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
46. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., Schwartz D., Yachnin T., Steinbruch S., Shapira I., Laniado S., Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780.
47. Palazzuoli A., Silverberg D., Iovine F., Capobianco S., Giannotti G., Calabrò A., Campagna S.M., Nuti R. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006, 152. 1096.e9-1096.15.
48. Ghali J.K., Anand I.S., Abraham W.T., Fonarow G.C., Greenberg B., Krum H., Massie B.M., Wasserman S.M., Trotman M.L., Sun Y., Knusel B., Armstrong P. Randomized double-blind trial of darbopoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117:526-535. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
49. McMurray J.J., Anand I.S., Diaz R., Maggioni A.P., O'Connor C., Pfeffer M.A., Polu K.R., Solomon S.D., Sun Y., Swedberg K., Tendera M., van Veldhuisen D.J., Wasserman S.M., Young J.B. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009, 11:795-801. RED-HF Committees and Investigators.
50. Asselbergs F.W., Diercks G.F., Hillege H.L., van Boven A.J., Janssen W.M., Voors A.A., de Zeeuw D., de Jong P.E., van Veldhuisen D.J., van Gilst W.H. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809-2816. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators.
51. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., Snapinn S., Cooper M.E., Mitch W.E., Brenner B.M. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-927.
52. Olsen M.H., Wachtell K., Ibsen H., Lindholm L.H., Dahlöf B., Devereux R.B., Kjeldsen S.E., Oikarinen L., Okin P.M. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006, 24:775-781. LIFE Study Investigators.
53. Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 SUPPL. 1):1-290.
54. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., Roccella E.J. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
55. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49:S12-154.
56. Rahman M., Pressel S., Davis B.R., Nwachuku C., Wright J.T., Whelton P.K., Barzilay J., Batuman V., Eckfeldt J.H., Farber M., Henriquez M., Kopyt N., Louis G.T., Saklayen M., Stanford C., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:936-946.
57. Casas J.P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A.D., MacAllister R.J. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026-2033.
58. O'Hare A.M., Kaufman J.S., Covinsky K.E., Landefeld C.S., McFarland L.V., Larson E.B. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?. Ann Intern Med 2009, 150:717-724.
59. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
60. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
61. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
62. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., Tsuyuki R.T., White M., Rouleau J., Latini R., Maggioni A., Young J., Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
63. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., Konstam M.A., Riegger G., Klinger G.H., Neaton J., Sharma D., Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-The Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
64. Pohl M.A., Blumenthal S., Cordonnier D.J., De Alvaro F., Deferrari G., Eisner G., Esmatjes E., Gilbert R.E., Hunsicker L.G., de Faria J.B., Mangili R., Moore J., Reisin E., Ritz E., Schernthaner G., et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial (IDNT): Clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027-3037.
65. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., Drury P.L., Esmatjes E., Hricik D., Pohl M., Raz I., Vanhille P., Wiegmann T.B., Wolfe B.M., Locatelli F., et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005, 16:2170-2179.
66. Costanzo M.R., Guglin M.E., Saltzberg M.T., Jessup M.L., Bart B.A., Teerlink J.R., Jaski B.E., Fang J.C., Feller E.D., Haas G.J., Anderson A.S., Schollmeyer M.P., Sobotka P.A. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683. UNLOAD Trial Investigators.
67. Verma A., Solomon S.D. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Curr Heart Fail Rep 2007, 4:183-189.
68. Chen Z.M., Pan H.C., Chen Y.P., Peto R., Collins R., Jiang L.X., Xie J.X., Liu L.S. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1622-1632. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.
69. McCullough P.A. Contrast induced nephropathy. J Am Coll Cardiol 2008, 51:1419-1428.
70. Nakayama M., Nakano H., Nakayama M. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol 2010, 55:49-54.
71. Iseki K. Chronic kidney disease in Japan. Intern Med 2008, 47:681-689.
72. Japanese Society of Nephrology Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 2009, 13:537-566.
73. Rule A.D., Teo B.W. GFR estimation in Japan and China: what accounts for the difference?. Am J Kidney Dis 2009, 53:932-935.
74. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Yamagata K., Tomino Y., Yokoyama H., Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.